Aquestive Therapeutics (AQST) Receivables - Net (2017 - 2026)

Aquestive Therapeutics' Receivables - Net history runs 10 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• On a quarterly basis, Receivables - Net fell 34.25% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 34.25% decrease from a year earlier, with the FY2025 full-year figure at $17.8 million, up 141.87% from the prior year.
• Receivables - Net slipped to $6.9 million in Q1 2026 per AQST's latest filing, from $17.8 million in the prior quarter.
• Across five years, Receivables - Net topped out at $19.9 million in Q1 2022 and bottomed at $4.7 million in Q4 2022.
• The 5-year median for Receivables - Net is $9.7 million (2024), against an average of $10.4 million.
• Across the five-year window, Receivables - Net soared 144.78% in 2022 and slumped 62.05% in 2023, its largest moves.
• Year by year, Receivables - Net stood at $4.7 million in 2022, then climbed by 18.41% to $5.6 million in 2023, then jumped by 31.85% to $7.3 million in 2024, then soared by 141.87% to $17.8 million in 2025, then slumped by 61.34% to $6.9 million in 2026.
• Per Business Quant, the three latest AQST Receivables - Net figures stand at $6.9 million (Q1 2026), $17.8 million (Q4 2025), and $11.8 million (Q3 2025).